From the Canadian Cancer Action Network website:

” Building on the launch of A Guide for Patient Advocacy Groups: How to provide patient and caregiver input for a pCODR drug review in 2013, the Canadian Cancer Action Network (CCAN) and the pan-Canadian Oncology Drug Review (pCODR) are pleased to continue our collaboration with the introduction of a new Patient Health Technology Assessment (HTA) Navigator, hired to provide a “live” resource to assist patient advocacy groups in navigating the pCODR process.

At this time, we wish to announce that we have engaged Suzanne Nurse, PhD, to lead our pilot project forward into 2015. This unique role represents a “Canadian first” model for HTA processes and is intended to provide patient groups with the support required to help optimize the patient submission for drugs under review by pCODR, as well as develop, identify and support opportunities for patient and carer/caregiver involvement relating to the pCODR program.

Funded by the Canadian Cancer Action Network, the role of Patient HTA Navigator reflects a shared CCAN/pCODR commitment to addressing the expressed needs of patient advocacy groups in Canada. We believe that patient input on drug reviews is important to the pCODR process as itensures patients’ and caregivers’ experiences of living with cancer and undergoing treatment are routinely considered, and we remain committed to collaboratively exploring innovative ways to best support patient groups in Canada.”

If you have any questions, please contact CCAN at and/or pCODR at “